| 余珊,方建明,李春媚,等.生物止血流体膜(术瑞吉)在内镜黏膜下剥离术中黏膜下注射的初步应用探讨[J].安徽医药,2026,30(9):1880-1885. |
| 生物止血流体膜(术瑞吉)在内镜黏膜下剥离术中黏膜下注射的初步应用探讨 |
| Exploration of the application of submucosal injection with biological hemostatic fluid membrane (Shu Rui Ji) in endoscopic submucosal dissection |
| |
| DOI：10.3969/j.issn.1009-6469.2026.09.034 |
| 中文关键词: 注射剂 黏膜下层 内镜黏膜下剥离术 透明质酸钠 海藻酸钠 羧甲基纤维素钠 生物止血流体膜 |
| 英文关键词: Injection Submucosa Endoscopic submucosal dissection Sodium hyaluronate Sodium alginate Sodium car boxymethyl cellulose Biological hemostatic fluid membrane |
| 基金项目:四川省医学会消化内镜专委会(捷祥)专项科研课题( 2021XHNJ13) |
| 作者 | 单位 | E-mail | | 余珊 | 攀枝花市中心医院, 消化内科,四川攀枝花 617000 | | | 方建明 | 攀枝花市中心医院,妇科,四川攀枝花 617000 | | | 李春媚 | 攀枝花市中心医院, 消化内科,四川攀枝花 617000 | | | 张慈 | 攀枝花市中心医院, 消化内科,四川攀枝花 617000 | | | 倪娜 | 攀枝花市中心医院, 消化内科,四川攀枝花 617000 | | | 王小明 | 攀枝花市中心医院, 消化内科,四川攀枝花 617000 | 1162531739@qq.com |
|
| 摘要点击次数: 276 |
| 全文下载次数: 39 |
| 中文摘要: |
| 目的初步探讨生物流体止血膜(术瑞吉)在内镜黏膜下剥离术( ESD)中黏膜下注射的可行性和安全性。方法前瞻性研究。 2021年 7月 5日于攀枝花五十四野猪林屠宰场购得 8个新鲜离体猪胃(屠宰后 2h内)，在新鲜离体猪胃黏膜下分别注射透明质酸钠(透明质酸钠组)和生物止血流体膜(术瑞吉)(术瑞吉组)测量并比较两组黏膜不同时间点隆起的高度。将 2021年 9月至 2023年 6月在攀枝花市中心医院消化内镜中心行内镜检查发现，的 40例早期胃癌黏膜病变符合 ESD绝对适应证的病人以随机数字表法分为研究组和对照组，各 20例。研究组 ESD术中黏膜下注射液采用生物止血流体膜(术瑞吉)，对照组黏膜下注射液采用透明质酸钠溶液。记录黏膜下注射液体总量及注射次数，手术时间及完整切除率，观察术中及术后有无严重的出血和穿孔。随访 1年，复查胃镜观察有无残留及复发。结果离体实验中术瑞吉组在起始及不同的时间点黏膜隆起的高度值与透明质酸钠组比较均差异无统计学意义( P>0.05)。体内实验研究组黏膜剥离平均耗费时间与对照组比较差异无统计学意义( P>0.05)，术中黏膜下注射液使用的总量( 30.5±10.6)mL低于对照组( 38.0±11.1)mL(P<0.05)；但是两组需要重复注射的病人例数相当。研究组术中大出血和穿孔、术后大出血的发生例数与对照组比较差异无统计学意义( P>0.05)两组术后均未出现迟发性穿孔。结论生物止血流体膜(术瑞吉)作为 ESD术中黏膜下注射液在一定程度上是初步具有可行性和安，全性的。 |
| 英文摘要: |
| Objective To preliminarily investigate the feasibility and safety of biological hemostatic fluid membrane (Shu Rui Ji) as a submucosal injection agent in endoscopic submucosal dissection (ESD). Methods A prospective study was conducted. On July 5,2021, eight fresh isolated pig stomachs ( within 2 h after slaughter ) were purchased from Panzhihua 54 Wild Boar Forest Slaughter.house, and sodium hyaluronate (sodium hyaluronate group) and biological hemostatic fluid membrane (Shu Rui Ji group) solution wereinjected into the fresh isolated pig gastric mucosa, respectively. The height of mucosal eminence was measured and compared betweenthe two groups at different time points. From September 2021 to June 2023, 40 patients with early gastric mucosal lesions eligible forESD (absolute indications) at the Digestive Endoscopy Center of Panzhihua Central Hospital were according to the random number ta.ble method assigned to the experimental group (Shu Rui Ji) and control group (sodium hyaluronate), with 20 cases in each group. Totalinjection volume, injection frequency, operation time, and complete resection rate were recorded. Intraoperative and postoperative se.vere bleeding and perforation were monitored. Follow-up gastroscopy was conducted over one year to assess residual and recurrence.Re. sults In vitro experiment, there was no statistically significant difference in the height of mucosal elevation at the initial point and dif.ferent time points between the Shu Rui Ji group and sodium hyaluronate group (P>0.05). In vivo experiments, the mean time requiredfor submucosal dissection in the experimental group showed no statistically significant difference compared with the control group (P> 0.05). The total injection volume of submucosal injection agent in the experimental group (30.5±10.6) mL was significantly lower thanthat in the control group (38.0±11.1) mL (P<0.05), while the number of patients requiring repeated injections was comparable betweenthe two groups. There was no statistically significant difference in the incidence of massive intraoperative bleeding and perforation, ormassive postoperative bleeding between the experimental group and the control group (P>0.05). No delayed perforation was reported in either group.Conclusion Biological hemostatic fluid membrane (Shu Rui Ji) as a submucosal injection solution during ESD is prelimi. narily feasible and safe to a certain extent. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
